

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD., CELLTRION INC,
and BIOCON BIOLOGICS INC.
Petitioners,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

Patent No. 11,253,572

Inter Partes Review No. IPR2023-00884¹

**PATENT OWNER'S UPDATED POWER OF ATTORNEY
UNDER 37 C.F.R. § 42.10(b)**

¹ IPR2024-00260 and IPR2024-00298 are joined with IPR2023-00884.

IPR2023-00884

Patent Owner, Regeneron Pharmaceuticals, Inc., hereby appoints the following practitioners as its attorneys to transact all business in the United States Patent and Trademark Office associated with the above-captioned *inter partes* review of U.S. Patent No. 11,253,572.

Adam R. Brausa, Reg. No. 60,287

Rebecca Weires, Reg. No. 77,895

Daralyn J. Durie, (*pro hac vice*, granted)

Kira A. Davis, (*pro hac vice*, granted)

David Caine, Reg. No. 52,683

Matthew M. Wilk, (*pro hac vice* to be filed)

Jeremy Cobb, (*pro hac vice* to be filed)

All attorneys at Morrison & Foerster LLP and Arnold & Porter Kaye Scholer LLP for whom a motion to appear *pro hac vice* is filed

The individual signing below has the authority to execute this document on

behalf of Regeneron Pharmaceuticals, Inc.:

By: 

Name: Frank R. Cottingham, Ph.D., J.D.

Title: VP, Associate General Counsel, Intellectual Property

Date: MARCH 14, 2024